Standard BioTools Inc. (NASDAQ:LAB) currently has a daily average trading volume of 292.09K but it saw 945265 shares traded on Thursday. With a market cap of 191.49M USD, stock’s current market price of $2.56 came rising about 1.99 while comparing to the previous closing price of $2.51. In past 52 weeks, the stock remained buoying in the range of price level as high as $2.61 and as low as $0.92. In the recent trading on the day, stock has struck highest price mark of $2.65 while lowest mark touched by it was $2.46.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Taking a look at 20-day trading activity of Standard BioTools Inc. (LAB) gives us an average price of $1.91, while its current price level is -1.92% below from 52-week high level whereas it is 178.26% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.90 while that of 200 days or SMA-200 reads an average of $1.62. A closer look into the stock’s movement over the week reveals that its volatility is standing at 8.34% during that period while stretching the period over a month that increases to 9.26%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 80.76 which implies that the stock is in overbought territory.
Standard BioTools Inc. (LAB)’s stock is currently under the radar of 1 analysts who are in consensus at a 12-month price target range of between $6.00 and $6.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $6.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $6.00. Average price target assigned by them is $6.00 which highlights an upside potential of 57.33% for the stock over that period. And to attain the median price target of $6.00 assigned by those analysts, stock has to add about 57.33% of value to its current levels.
Data by FactSet Research shows that 1 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 1 analysts suggested the investors to Buy the stock while 0 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Buy for the stock and that issued by Wall Street to investors is Moderate Buy.
Over the week, LAB’s stock price is moving 17.16% up while it is 55.15% when we observe its performance for the past one month. Year-to-date it is 118.80% up and over the past year, the stock is showing an upside performance of 31.28%.
The latest quarterly earnings report issued by the company was for quarter ended 3/30/2023, when its quarterly earnings per share (EPS) of $0 beat the consensus estimate of $0 for the same. The company is expected to be releasing its next quarterly report in 08/03/2023, for which analysts forecasted an EPS of $0 while estimate for next year EPS is -$0.01.
Currently, Standard BioTools Inc.’s total number of outstanding shares is 79.08M with 2.22% of that held by the insiders while 64.70% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 683.00% and return on equity (ROE) at 187.40%. Stock’s beta reads 1.51. Stock has a price to sale or P/S ratio amounts to 1.98. Its return on asset (ROA) is -32.30% on average.
As per SEC documents, Needham Small Cap Growth Fund shunned 3,647,157 of company’s common stock of worth $6.2 million as per recent closing price of the stock. Needham Small Cap Growth Fund is not the only institutional holder which restructured its stake in Standard BioTools Inc., as PRIMECAP Odyssey Aggressive Growt dumped 3,613,862 shares of worth $6.14 million to bring its holdings to a total of -0.12 million shares.
